Implementing and Validating Meso Scale Discovery – ECL Detection for Clinical Trials
When implementing biomarker strategies for clinical trials, it is not only important to choose the right analysis platform but also have the assays validated and performed to meet regulatory submission requirements.
Unilabs Serving Pharma group, in collaboration with Meso-Scale Discovery (MSD) will present the capabilities and opportunities for the use of the MSD-ECL platform for biomarker analysis in clinicals trials.
Unilabs experienced scientific team will share their experience and offer guidance on how to set-up and validate the MSD platform, and which important aspects to consider.
Date: 8th June 2021
Time: 10:00 – 11:00
|9:50||Online platform opens for registering participants|
|10:00||Welcome and introduction of speakers|
David Munis Zepernick, Head of Business Development and Public Affairs, Medicon Valley Alliance
|10:05||Advances in Multiplex ECL Detection of Protein Biomarkers|
Anders Elleby, Meso-Scale Diagnostics
|10:30||Practical Considerations for Biomarker Validation in Clinical Trials|
Colin Farrell, Ph.D. Unilabs
|11:00||End of webinar|
Organized in collaboration with